Mitomycin (MM)

DRUG2 trials

Sponsors

University of Sydney, Maimónides Biomedical Research Institute of Córdoba

Conditions

Bladder CancerLocally Advanced Colorectal Cancer

Phase 3

Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer

University of SydneyBladder Cancer

Start: 2013-07-31End: 2024-12-31Updated: 2023-06-18

Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer

Not yet recruitingNCT06783491

Maimónides Biomedical Research Institute of CórdobaLocally Advanced Colorectal Cancer

Start: 2025-12-31End: 2030-12-31Target: 1083Updated: 2025-11-24

Related Papers

Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: A randomized phase 3 trial (ANZUP 1301).

Journal of Clinical Oncology2025-06-043 citations

Adding mitomycin (MM) to bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non–muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301.

Journal of Clinical Oncology2023-06-011 citations

Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301).

Journal of Clinical Oncology2020-02-192 citations